Tyra Biosciences Inc

TYRA.US
Healthcare · Biotechnology
30.88
-0.18 (-0.58%)
USD · NASDAQ

Company Information

Company Name
Tyra Biosciences Inc
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US90240B1061
CIK: 0001863127
CUSIP: 90240B106
Currency: USD
Full Time Employees: 87
Phone: 619 728 4760
Fiscal Year End: December
IPO Date: Sep 15, 2021
Description:

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

Address:

2656 State Street, Carlsbad, CA, United States, 92008

People

Directors & Officers

Name Title Year Born
Dr. Todd Harris Ph.D. Co-Founder, CEO, President & Director 1979
Mr. Bhavesh Ashar M.B.A. Chief Operating Officer 1969
Dr. Douglas Warner M.D. Chief Medical Officer 1972
Mr. Daniel Bensen Co-Founder & Chief Discovery Officer 1975
Ms. Julia Rueb VP of Finance & Principal Accounting Officer 1986
Dr. Robert L. Hudkins Ph.D. Chief Technology Officer 1955
Dr. Ronald V. Swanson Ph.D. Chief Scientific Officer 1963
Mr. Ali D. Fawaz J.D. General Counsel & Secretary NA
Ms. Sarah Honig Senior VP of Corporate Development & Strategy NA
Liz Pagano Chief Human Resources Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Mar 25, 2026 Gilla Kaplan N/A Sale 14.30K $36.97 $528.49K
Dec 19, 2025 Robert J More N/A Sale 10.00K $25.00 $250.00K
Nov 21, 2025 Robert J More N/A Sale 246.87K $20.25 $5.00M
Jun 18, 2025 Gilla Kaplan N/A Sale 9.57K $9.78 $93.58K
Jun 17, 2025 Gilla Kaplan N/A Sale 10.00 $10.35 $103.50
Jun 16, 2025 Gilla Kaplan N/A Sale 6.81K $10.38 $70.73K
Jun 13, 2025 Gilla Kaplan N/A Sale 15.00K $10.31 $154.65K
Jun 12, 2025 Gilla Kaplan N/A Sale 30.00K $10.31 $309.30K

Shareholders

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
RA Capital Management, LLC 12.20M Mar 31, 2026 20.51% $4.95 0.00%
FMR Inc 7.75M Mar 31, 2026 13.03% $0.02 61,570.37%
Nextech Invest, Ltd. 4.06M Mar 31, 2026 6.82% $10.93 0.00%
HHG PLC 3.89M Mar 31, 2026 6.54% $0.07 32.54%
Alta Partners Management Company, L.P. 3.82M Jun 30, 2026 6.43% $95.92 0.00%
Farallon Capital Management, L.L.C. 3.58M Mar 31, 2026 6.02% $0.78 73.25%
TCG Crossover Management, LLC 3.25M Mar 31, 2026 5.46% $3.56 12.11%
COMMODORE CAPITAL LP 2.48M Mar 31, 2026 4.16% $5.48 -26.67%
BlackRock Inc 2.22M Mar 31, 2026 3.73% $0.00 6.30%
Paradigm Biocapital Advisors LP 2.05M Mar 31, 2026 3.46% $1.61 0.00%
Bvf Inc 1.98M Mar 31, 2026 3.32% $2.41 -7.12%
Vanguard Group Inc 1.57M Dec 31, 2025 2.64% $0.00 3.46%
Caligan Partners LP 1.28M Mar 31, 2026 2.15% $3.25 35.24%
State Street Corp 1.22M Mar 31, 2026 2.04% $0.00 62.26%
Vanguard Capital Management, LLC 1.13M Mar 31, 2026 1.89% $0.00 0.00%
5AM Venture Management, LLC 1.03M Mar 31, 2026 1.73% $10.94 0.00%
T. Rowe Price Associates, Inc. 986.06K Mar 31, 2026 1.66% $0.00 6,732.46%
Logos Global Management LP 850.00K Mar 31, 2026 1.43% $1.63 304.76%
Barclays PLC 833.40K Mar 31, 2026 1.40% $0.01 992.14%
Canaan Partners XI LLC 750.00K Jun 30, 2026 1.26% $18.82 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity OTC 3.28M 5.51% ▲ 0.00% May 31, 2026
2 State Street® SPDR® S&P® Biotech ETF 1.39M 2.33% ▼ 2.18% Jun 30, 2026
3 Vanguard Total Stock Mkt Idx Inv 1.14M 1.91% ▲ 35.79% Jun 30, 2026
4 iShares Russell 2000 ETF 949.84K 1.60% ▲ 0.60% Jun 30, 2026
5 T. Rowe Price New Horizons 793.14K 1.33% ▲ 102.57% Jun 30, 2026
6 US Small-Cap Growth II Equity Comp 793.14K 1.33% ▲ 258.11% Jun 30, 2026
7 Fidelity Advisor Equity Growth I 678.60K 1.14% ▲ 0.00% May 31, 2026
8 Fidelity VIP Growth Initial 630.80K 1.06% ▲ 0.00% May 31, 2026
9 T. Rowe Price Integrated US SmCapGrEq 558.50K 0.94% ▲ 248.19% Jun 30, 2026
10 T. Rowe Price Integrated US Sm Gr Eq 558.50K 0.94% ▲ 118.51% Jun 30, 2026

Financial Highlights

Market Cap: $1.85B
EBITDA: $-142.37M
Book Value: $4.83
Earnings/Share: $-2.21
Profit Margin: 0.00%
Operating Margin: 0.00%
ROA (TTM): -23.64%
ROE (TTM): -36.87%
Revenue (TTM): $0.00
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 0.00%

Valuation Metrics

Enterprise Value: $1.44B
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 59.47M
Shares Float: 30.92M
% Insiders: 286.00%
% Institutions: 11,174.40%
Short % Float: 30.87%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

Open full waterfall
Line Item
Step Type
Value
Revenue
adjust
$0.00
Cost of Goods Sold
adjust
$-546.00K
Gross Profit
subtotal
$-546.00K
SG&A
adjust
$-29.83M
R&D
adjust
$-102.93M
Operating Income
subtotal
$-132.76M
Other / Non-Operating Items
adjust
$12.82M
Net Income
subtotal
$-119.95M

Earnings Per Share (EPS) History

Financial Ratios

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about TYRA.US!